Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Solid Tumor 1Neoplasms 1Keratosis, Actinic 1

Interventions

Nivolumab 4pertuzumab 2pembrolizumab 2durvalumab 2Paclitaxel 2Docetaxel 2Capecitabine 2ulocuplumab 1tremelimumab 1tazarotene 1talazoparib 1romiplostim 1pexidartinib 1pamiparib 1onartuzumab 1magrolimab 1entrectinib 1cobimetinib 1atezolizumab 1Sunitinib 1Rifampin 1Ramucirumab 1Radiosurgery 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Midazolam 1MK-4166 1LY3022855 1LY2510924 1LY-2157299 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumor × tazarotene × Clear all
NCT04071756 2024-02-07

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 12 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡